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Abstract
Background: Chronic HCV infection combined with occult hepatitis B infection has been associated with liver
enzymes flare, advanced hepatic fibrosis and cirrhosis, poor response to standard interferon-a, and increased risk of
HCC. This study aimed to elucidate the prevalence of occult hepatitis B infection in Egyptian chronic HCV patients,
and to clarify its role in non-response of those patients to pegylated interferon/ribavirin therapy. This study
enrolled 155 consecutive chronic HCV patients under pegylated interferon/ribavirin therapy. All patients were
exposed to clinical assessment, biochemical, histological and virological examinations. HBV parameters (HBV DNA,
anti-HBc, anti-HBs) and patients’ response status to the combination therapy were determined.
Results: In this study, occult hepatitis B infection occurs in 3.9% of Egyptian chronic HCV patients; tends to affect
younger age patients, associated with higher base line HCV viral load, less hepatic fibrosis than monoinfected
patients. This occult hepatitis B infection is not a statistically significant cause of non-response to pegylated
interferon/ribavirin therapy. Anti-HBs was not associated with any biochemical, histological or virological
abnormalities in those patients, contrary to low response rate to therapy and higher HCV viral load that was
observed with anti-HBc.
Conclusions: Detection of HBV DNA in HBsAg negative chronic HCV patients plays a non significant role in non-
response of Egyptian patients to pegylated interferon/ribavirin therapy.
Background
Chronic hepatitis C (HCV) affects more than 170 mil-
lion people worldwide, causing cirrhosis and liver cancer
[1]. In Egypt, high HCV rates were reported reaching up
to 20% [2]. The currently recommended therapy for
chronic HCV is the combination of pegylated interferon
alpha and ribavirin (Peg-IFN/RBV) that proved to be
superior to standard interferon alpha and ribavirin [3].
More than 50% of patients can achieve a sustained viro-
logical response (SVR) after 24-48 weeks of this combi-
nation therapy, making HCV a potentially curable
disease [1]. For patients with HCV genotype 4 infections
(the prevalent genotype in Egypt), combination treat-
ment with pegylated interferon alpha and weight based
ribavirin administered for 48 weeks seems to be an
appropriate regimen [4]. Occult hepatitis B virus infec-
tion (OBI) is defined as the presence of HBV DNA, in
serum and/or the liver tissue without detectable HBsAg
with or without anti-HBc or anti-HBs outside the pre-
seroconversion window period [5]. Both HBV and HCV
share common routes of transmission and hence there
is a consensus that patients with chronic HCV liver dis-
ease, are at high risk of OBI [6,7]. OBI may contribute
to liver inflammation through episodes of increased viral
replication, increased immune activity and subsequent
liver injury [8].
I nc h r o n i cH C Vi n f e c t i o n ,t h ep r e s e n c eo fO B Ih a s
been associated with liver enzymes flare [8], increased
severity of liver disease towards advanced fibrosis and
cirrhosis [6,9], poor response to standard interferon-a in
many [6,9-12], but not all [13] studies, and increased
risk of HCC [14,15].
Although the potential mechanism for reduced inter-
feron response in these cases remains unclear, one
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tic expression of interferon receptor mRNA and protein
in OBI [12].
Some studies suggested a negative influence of OBI on
the response to standard interferon in chronic HCV
infection [6,9-12]. This observation needs to be con-
firmed in HCV populations treated with the standard of
care Peg-IFN/RBV combination therapy [16].
This study aimed to elucidate the prevalence of OBI in
Egyptian chronic HCV patients, and to clarify its role as
a cause of non-response of those patients to the stan-
dard of care Peg-IFN/RBV therapy.
Patients and methods
The ethical committee of our institution approved this
study to be conducted at both Al-Ahrar General Hospi-
tal and Zagazig University Hospitals, Sharkia Governor-
ate, Egypt, and included 155 chronic HCV patients
under Peg-IFN/RBV therapy. The diagnosis of HCV was
confirmed by detection of anti-HCV antibody and HCV
RNA and they were all candidates to begin the combi-
nation therapy according to the guidelines of the
national Committee for Control and Prevention of viral
Hepatitis “C” in Egypt, with the following criteria:
Inclusion criteria
1. Age:18-60 years.
2. White blood cells > 4000/mm
3
3. Neutrophils > 2000/mm
3.
4. Platelets > 85000/mm
3.
5. Prothrombin time < 2 seconds above upper limit of
normal (ULN).
6. Direct bilirubin 0.3 mg/dl.
7. Indirect bilirubin 0.8 mg/dl.
8. Albumin > 3.5 gm/dl.
9. Serum creatinine, Fasting blood sugar, TSH within
normal limits.
10. HBsAg: Negative.
11. ANA < 1:160.
12. Positive for anti-HCV and HCV RNA.
13. If diabetic, HB A1C < 8.5%.
14. Alpha feto-protein <100 IU/ml., but If is >100, C.
T. is normal.
15. Females practice adequate contraception.
16. Male patient’s wife practicing adequate
contraception.
17. Signed written informed consent for the study.
Exclusion criteria
Exclusion of,
1. Any other cause of chronic liver disease other than
HCV (by liver biopsy).
2. Overt HBV Co-infection
3. Autoimmune disease (by ANA).
4. Alcoholic liver disease.
5. Decompensated liver disease.
6. Hypersensitivity to Peg-IFN/RBV.
7. Pregnancy or breast feeding.
8. Poorly controlled diabetes.
9. Clinically significant retinal abnormalities.
10. Obesity -induced liver disease.
11. Drug-induced liver disease.
12. CNS trauma or active seizures which requires
medication
13. Ischemic cardiovascular insult within the last 6
months.
14. Immunologically mediated diseases.
15. Patients with organ transplant.
16. Substance abuse (abstention for the last 12
months).
17. Immunosuppressive drugs.
18. Severe pre-existing psychiatric conditions.
Patients
In this cross sectional study, patients were divided into
two groups according to their HBV DNA status:
Group I: Patients having HBV DNA positivity (dually
infected patients).
Group II: Patients negative for HBV DNA (monin-
fected patients).
All the studied patients were subjected to the
following:
I-Clinical assessment
History taking, BMI, physical examination.
II. Biochemical assessment
Liver function tests, kidney functions, complete blood
counts, serum uric acid, cholesterol and triglycerides,
HCV RNA both pre-enrollment and during treatment
were examined.
III. Liver biopsy
Pathological examination performed at liver histopathol-
ogy laboratory, Faculty of Medicine, Zagazig University.
More than one pathologist revised the slides to minimize
inter-observer variability that commonly affects explana-
tion of liver biopsy. Liver biopsies were paraffin-embedded
and stained with haematoxylin-eosin and Masson tri-
chrome stains, additional stains were used when needed.
The biopsies were reviewed blindly without knowledge of
any parameter. Hepatitis grading and staging were evalu-
ated according to the METAVIR scoring system [17].
IV. Serodiagnosis of HBV
anti-HBc total antibodies were detected by a rapid
immunoassay (Gold Colloidal Conjugate Membrane,
Cal-Tech Diagnostics, INC.- California, USA) while
anti-HBs antibodies were determined by the electro-
chemi-luminescence immunoassay “ECLIA” technique
using commercially available kits (Cobas e 411 analy-
zer, Hitachi, Japan).
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The assay (done while the patients were under Peg-IFN/
RBV therapy) and results were performed and inter-
preted by investigators who were blinded to the patients’
baseline characteristics, HBV serology and stage of liver
biopsy. We used COBAS® AmpliPrep/COBAS® TaqMan®
HBV Test (Roche Diagnostics, Switzerland), which is a
real time quantitative PCR technology. Specimen pro-
cessing carried out by COBAS AmpliPrep analyzer, spe-
cimens were collected by professional staff with sticking
to quality standards to avoid any potential contamina-
tion, blood was collected in EDTA containing tubes,
transfer of the specimen within the laboratory was
maintained at 2-8°C, most samples were analyzed on the
same day, while when stored for no more than 3 days,
they were kept at room temperature (25-30°C). The
concentration of HBV DNA in EDTA-plasma that can
be detected with a positivity rate of greater than 95% is
12 IU/mL or lower while its specificity is 100%.
Treatment regimens and follow up
The dose of peginterferon is given subcutaneously
around the umbilicus once per week, the dose of alpha-
2a is 180 ug together with ribavirin, using 1000 mg/day
for those ≤75 kg in weight and 1200 mg/day for those
>75 kg in weight; while the dose of alph-2b is 1.5 ug/kg
body weight together with ribavirin at dose of 800 mg/
day for those weighting <65 kg; 1000 mg for those >65
kg to 85 kg; 1200 mg for those >85 kg to 105 kg; and
1400 mg for those > 105 kg.
Patient Monitoring
All the patients attended to the Viral Hepatitis out-
patient Clinic for monitoring during treatment. Patients
were assessed at weeks 0, 1, 2 and 4 of treatment and
thereafter monthly. At each review, laboratory tests were
performed including serum ALT and AST, bilirubin, full
blood count, and serum creatinine. Body weight and
symptom checklist were recorded at each visit and dose
modifications to the Peg-IFN or ribavirin were made
when appropriate. Quantitative serum HCV-RNA was
determined at baseline and at week 12. Qualitative
HCV-RNA was determined at weeks 24 and 48.
Statistical analysis
Data were checked, entered and analyzed using SPSS
version 13 for data processing and statistics.
Results
The base line characters of all patients are described in
( t a b l e1 ) .O u to ft h e1 5 5e xamined chronic HCV
patients, only 6 patients (3.9%) had OBI. Comparison
between OBI/HCV dually infected and HCV monoin-
fected patients showed that, dually infected patients are
younger in age 32.8 years (p = 0.013), had less advanced
hepatic fibrosis (p = 0.02), and higher base line HCV
v i r a ll o a d( p=0 . 0 0 6 )t h a nm o n o i n f e c t e dp a t i e n t s .
Whereas, sex, BMI, liver enzymes, histological activity,
HBV serological markers and response rates to Peg-
IFN/RBV were comparable between the two groups
(table 2).
Anti-HBc was associated with higher base line HCV
viral load 9.43 × 10
5 IU/ml (p < 0.001) and poor
response to the combination therapy (p = 0.018), while
no relation to histological indices, liver enzymes, HBV
DNA nor to Anti-HBs antibodies (table 3).
Anti-HBs was not associated with any demographic, bio-
chemical, histological, serological parameter abnormality
Table 1 Characters of the studied patients.
Number 155
Age(years)
X
- ± SD 41.8 ± 9.2
Range 19-59
Sex
M 125 80.6%
F 30 19.4%
BMI
X
- ± SD 27.3 ± 3.6
Range 21- 40.5
Duration of HCV infection (years)
X
- ± SD 4.4 ± 3.6
Range 1-19
Smoking status
Non 81 52.2%
Active 57 36.8%
Ex-smoker 17 11.0%
Basal ALT (× ULN)
≤2 116 74.8%
>2 39 25.2%
Basal AST (× ULN)
≤2 124 80%
>2 31 20%
Activity
1 52 33.6%
2 71 45.8%
3 32 20.6%
Fibrosis
1 54 34.8%
2 61 39.4%
3 36 23.2%
4 4 2.6%
Basal HCV Viral Load (IU × 10
5)
X
- ± SD 3.87 ± 5.7
Range 0.001-22.3
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positive and negative patients (table 4).
All dually infected patients were males <40 years of
age, had F2 hepatic fibrosis, A1-2 histological activity,
all were non-responders to combination therapy, and
2 patients had HCV viral load at time of examination
higher than the base line levels (table 5).
Discussion
The incidence of OBI in HCV patients varies greatly,
ranging from 0%-52% [9,11], in this study the incidence
of OBI is 3.9% (only 6 cases of detectable serum HBV
DNA with mean HBV DNA level of 1726.2 IU/ml) this
low prevalence is in agreement with the rates reported
by many investigators [18-20].
Our study, like many other studies, examined only one
serum sample, which may not be sufficient to detect
OBI if the viral replication is intermittent, and this
together with the assumption that OBI is sensitive to
Peg-IFN therapy and the intermediate prevalence of
HBV in Egypt, 2-8% HBsAg carrier rate [21], may
account for the low prevalence of OBI in this study.
Table 2 Biochemical, pathological and virological parameters in HBV/HCV dually infected and HCV mono-infected
patients.
Occult HBV/HCV Dual Infection
(n = 6)
HCV Monoinfection
(n = 149)
Test P
Age (years) t Test
X
- ± SD 32.8 ± 6.3 42.2 ± 9.1 2.48 0.013*
Range 20 - 36 19 - 59
Sex No. %N o . %X
2
M 6 100.0 119 79.9 0.49 0.48
F 0 0.0 30 20.1
BMI t Test
X
- ± SD 25.7 ± 1.5 27.3 ± 3.6 1.1 0.27
Range 24 - 27.5 21 - 40.5
Basal ALT (× ULN) No. %N o . %X
2
≤2 6 100.0 112 75.2 0.83 0.36
>2 0 0.0 37 24.8
Basal AST (× ULN) No. %N o . %X
2
≤2 4 66.7 122 81.9 0.16 0.68
>2 2 33.3 27 18.1
Activity No. %N o . %X
2
1 2 33.3 50 33.6 1.88 0.39
2 4 66.7 67 44.9
3 0 0.0 32 21.5
Fibrosis No. %N o . %X
2
1 0 0.0 54 36.2
2 6 100.0 55 36.9 9.62 0.02*
3 0 0.0 36 24.2
4 0 0.0 4 2.7
Basal HCV Viral Load (IU × 10
5) t Test
X
- ± SD 10.05 ± 9.93 3.62 ± 5.4 2.74 0.006*
Range 0.4 - 22.3 0.001 - 22
Anti-HBc No. %N o . %X
2
Negative 4 66.7 133 89.3 1.09 0.29
Positive 2 33.3 16 10.7
Anti-HBs No. %N o . %X
2
Negative 6 100.0 131 87.9 0.07 0.79
Positive 0 0.0 18 12.1
Response Rate No. %N o . %X
2
Responder 0.0 0.0 70 46.98 3.42 0.06
Non-responder 6.0 100 79 53.02
* Significant
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< 200 IU/ml and recent definitions of OBI included
liver HBV DNA positivity as a prerequisite for consider-
ing OBI [16], but examination of liver tissue is not
always applicable in clinical practice [20,22], and that is
why highly sensitive PCR assays with low detection limit
should be used in diagnosis of OBI [23]. In this aspect
Levast et al., (2010) [22] reported liver tissue HBV DNA
in 5 out of 113 (4.4%) chronic HCV and none had
serum HBV DNA. If occurrence of OBI is thought to be
due to strong inhibition HBV replication by the immune
system, it thus would be expected to find low levels of
HBV DNA in positive cases and this may explain their
results [22].
There is a reciprocal inhibition of replication between
both HBV and HCV, with dominance of HCV inhibitory
effect on HBV replication by its core protein [24], there-
fore HBV may flare up when the HCV virus is treated
[25], and this may explain the slightly high levels of
HBV DNA (> 2000 IU/ml) reported in 4 cases of our
study, although this is a possible explanation, yet it is
not conclusive because we evaluated HBV DNA at only
one point of time. If occurrence of OBI would be due to
HBV surface mutants, that test negative for HBsAg by
the commonly available commercial kits [26], and that
m a yh a v el e v e l so fv i r a e m i ac o m p a r a b l et oo v e r t
Table 3 Anti-HBc status among studied patients.
Anti HBc Test P
Positive
(n = 18)
Negative
(n = 137)
Age (years) t
Test
X
- ± SD 43.4 ± 9.1 41.6 ± 9.2 0.79 0.43
Range 28-59 19-59
Sex No. %N o . %X
2
M 16 88.9 109 79.6 0.39 0.53
F 2 11.1 28 20.4
Activity No. %N o . %X
2
1 2 22.15 50 36.5
2 12 66.7 59 43.1 5.02 0.08
3 4 22.15 28 20.4
Fibrosis No. %N o . %X
2
1 4 22.2 49 35.7
2 6 33.3 56 41.0 5.55 0.13
3 8 44.4 28 20.4
4 0 0.0 4 2.9
Basal HCV Viral Load (IU ×
10
5)
t
Test
X
- ± SD 9.43 ± 9.9 3.1 ± 4.5 4.66 <
0.001*
Range × 10
5 0.62-22.3 0.001-21
Basal ALT(× ULN) No. %N o . %X
2
≤ 2 14 77.8 102 74.5 0.001 0.98
> 2 4 22.2 35 25.5
Basal AST (× ULN) No. %N o . %X
2
≤ 2 16 88.9 108 78.8 0.48 0.49
> 2 2 11.1 29 21.2
HBV DNA No. %N o . %X
2
Positive 2 11.1 4 2.9 1.09 0.29
Negative 16 88.9 133 97.1
Response Rate No. %N o . %X
2
Responder 4 22.2 66 48.2 5.58 0.018*
Non-responder 14 77.8 71 51.8
Anti-HBs No. %N o . %X
2
Positive 4 22.2 14 10.2 1.22 0.26
Negative 14 77.8 123 89.8
* Significant
Table 4 Anti-HBs status among studied patients.
Anti HBs Test P
Positive
(n = 18)
Negative
(n = 137)
Age (years) t Test
X
- ± SD 43.4 ± 6.5 41.6 ± 9.5 0.79 0.43
Range 29-53 19-59
Sex No. %N o . %X
2
M 16 88.9 109 79.6 0.39 0.53
F 2 11.1 28 20.4
Activity No. %N o . %X
2
1 7 38.9 45 32.8
2 11 61.1 60 43.8 5.42 0.06
3 0 0.0 32 23.4
Fibrosis No. %N o . %X
2
1 4 22.2 50 36.5
2 12 66.7 49 35.8 6.6 0.08
3 2 11.1 34 24.8
4 0 0.0 4 2.9
Basal HCV Viral Load (IU × 10
5) t Test
X
- ± SD 2.3 ± 3.9 4.1 ± 5.9 1.24 0.21
Range 0.006-12.9 0.001-22.3
Basal ALT (× ULN) No. %N o . %X
2
≤2 16 88.9 102 74.5 1.12 0.29
>2 2 11.1 35 25.5
Basal AST (× ULN) No. %N o . %X
2
≤2 18 100 108 78.8 4.69 0.03
>2 0.0 0.0 29 21.2
HBV DNA No. %N o . %X
2
Positive 0 0.0 6 4.4 0.82 0.36
Negative 18 100 131 95.6
Response Rate No. %N o . %X
2
Responder 10 55.6 60 43.8 0.89 0.34
Non-responder 8 44.4 77 56.2
Anti-HBc No. %N o . %X
2
Positive 4 22.2 14 10.2 1.22 0.26
Negative 14 77.8 123 89.8
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high serum HBV DNA levels in our study. Long lasting
persistence of HBV in the liver may provoke a mild but
continuing necroinflammation, that, if other causes of
liver damage (such as HCV) co-exist, may over time
contribute to progression of chronic liver disease to cir-
r h o s i s[ 8 , 2 8 ] ,t h i si ss h o w ni no u rp a t i e n t sw h e r ea l l
dually infected patients were F2 and 4 cases were A2.
In this study OBI could not be predicted by serologi-
cal markers of HBV infection, where only 2 out of the 6
patients with detectable HBV DNA had anti-HBc anti-
bodies, and none had anti-HBs antibodies. Anti-HBc
antibody was present in 18 patients with incidence of
11.6%. Anti-HBc was associated with anti-HBs in 4
patients (2.6%), while anti-HBc only state was reported
in 14 patients (9%). This can be explained by the notion
that following HBV infection both anti-HBs and anti-
HBc antibodies develop, while titres of anti-HBs
decreases over years to undetectable levels, anti-HBc
antibodies only persists [29].
We reported non significant differences in histological
activity and fibrosis between anti-HBc positive and
negative patients and also between anti-HBc positive/
DNA positive and anti-HBc positive/DNA negative
patients, these results disagree with Yuki et al. (2003)
[30] and El-Sharaway et al. (2007) [31]. Our results are
in agreement with those of Chen et al. (2010) [19]and
Levast et al. (2010) [20], who reported lower and similar
rates of histological activity and hepatic fibrosis between
OBI/HCV patients and HCV monoinfected patients
respectively. These results seems not to be related to
HCV genotypes, where our patients are mostly of geno-
type 4, that is known in Egypt to be extremely variable,
not only in terms of sequence, but also in terms of
functional and immunological determinants [32] in
comparison to non-genotype 4 in their studies.
Anti-HBc is associated with higher basal HCV viral
load and non-response to Peg-IFN/RBV therapy, but
these findings needs to be confirmed in further studies,
especially with the trend in the literature to neglect ser-
omarkers of HBV in defining OBI.
Anti-HBs was not linked to non-response to IFN ther-
apy in previous studies; this is also applied to our study,
where no statistically significant difference as regard
response rates to Peg-IFN based therapy was noticed.
But, it should be evident that anti-HBs positive cases
showed no correlation to advanced necroinflammation
and fibrosis in our study, in contrast to what had been
noticed by some authors [33].
As regard to impact of OBI on the response to stan-
dard interferon/ribavirin therapy, authers found a non
significant results between patients with and without
OBI [13,34-36]. In contrast low response rates were
recorded in chronic HCV patients with OBI under stan-
dard interferon monotherapy [6,9-12]. Our study uses
the standard of care Peg-IFN/RBV therapy, that poten-
tially cures OBI. Levast et al., (2010) [20], conducted ret-
rospective analysis of 140 patients treated for chronic
HCV by Peg-IFN/RBV. They confirmed the lack of asso-
ciation between HBV markers (HBV DNA, anti-HBc,
and anti-HBs antibodies) and disease severity or
response to treatment, we reported similar findings for
HBV DNA and anti-HBs while anti-HBc was linked to
non-response to the combination therapy.
Chen et al., (2010) [19] concluded that, OBI was rare
in HCV, virological and biochemical features between
OBI/HCV patients and HCV monoinfection patients
were comparable, these findings are similar to our
Table 5 Characteristics of the six HBV/HCV dually infected patients.
Patient 1 2 3 4 5 6
Age (years) 20 36 21 37 35 34
Sex MM M M M M
Baseline ALT (× ULN) 1.5 1 1.5 1 1 1
Duration of HCV Infection (years) 1 13 2 12 2 2
PostTreatment ALT (× ULN) 1 1 1 1 0.5 0.5
COBAS HBV DNA Level (IU/ml) 2980 2210 2880 2010 128 149
Serological Status
Anti-HBc -ve +ve -ve +ve -ve -ve
Anti-HBs -ve -ve -ve -ve -ve -ve
METAVIR Score
Activity (A) A2 A2 A2 A2 A1 A1
Fibrosis (F) F2 F2 F2 F2 F2 F2
Basal HCV Load (IU/ml) 0.4 × 10
5 22.3 × 10
5 0.39 × 10
5 22.1 × 10
5 7.2 × 10
5 7.23 × 10
5
Post-Treatment HCV Load (IU/ml) 1.4 × 10
5 6×1 0
5 1.38 × 10
5 5.59 × 10
5 0.0028 × 10
5 0.027 × 10
5
Response to IFN NR NR NR NR RR RR
M, male, F, female. -ve, negative, +ve, positive, NR, non responder, RR, relapse
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was low and patients with OBI responded to Peg-IFN/
RBV therapy, in contrast to high HBV DNA load in our
patients and lack of response in our 6 patients, this may
be related to HBV genotypes, where HBV genotype D is
the prevalent genotype in Egypt.
Patients with HCV/HBV dual infection were noticed
to have high HCV RNA load than those with HCV
mono-infection [11,37]. This seems to be applicable to
genotype 4, where HBV DNA positive patients in our
study showed higher baseline HCV viral load than HCV
monoinfected patients. Suppression of the dominant
virus -usually HCV predominates over HBV- may be
associated with flares of the non-dominant virus, and
this notion is reflected by the relatively high levels of
HBV DNA in our positive cases (1726.1 IU/ml), in com-
parison to 200 IU/ml proposed by Raimondo et al. [16]
and 923 IU/ml reported by Chen et al. [19], this may be
related to viral genotypes where our cases are HCV gen-
otype 4 and HBV genotype D whose clinical impact has
been studied less extensively [38].
HBV DNA positive cases in our study tends to be of
younger age group (32.8 ± 6.3 years), this may be due to
more risk of exposure to infection
Conclusions
In conclusion, detection of HBV DNA in HBsAg negative
Egyptian chronic HCV patients is not a statistically signifi-
cant cause of non-response of those patients to the current
standard of care Peg-IFN/ribavirin therapy, and hence rely-
ing on the available data it is not currently recommended
to screen for OBI in chronic HCV before initiation of anti-
viral therapy. The finding that anti-HBc antibody may be
associated with non-response to antiviral therapy needs
further confirmation. Anti-HBs seems to have no relation
with any biochemical, pathological nor virological aspects
in these patients. Dually infected patients are of younger
age group, had higher baseline HCV viral load and were
non responders to antiviral therapy.
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